Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.
- First Phase 3 clinical site activated at Monash Children’s Hospital
- Multi-centre, randomised, placebo-controlled trial design
- Evaluating NTI164’s efficacy and safety in paediatric Autism Spectrum Disorder
- Planned enrolment of 150 patients with adaptive trial design
- Additional clinical sites to open in coming months
Neurotech Advances Autism Treatment Trial
Neurotech International Limited (ASX:NTI) has taken a significant stride forward in its clinical development program by initiating the first site for its Phase 3 “Beyond Harmony” trial. The trial, which focuses on evaluating NTI164 in children diagnosed with Autism Spectrum Disorder (ASD), has commenced patient recruitment at Monash Children’s Hospital, a leading paediatric research facility in Australia.
This Phase 3 study is designed as a multi-centre, randomised, double-blind, placebo-controlled trial; the gold standard in clinical research. It aims to rigorously assess the efficacy, safety, and tolerability of NTI164, a proprietary cannabinoid formulation that targets both the core behavioural symptoms of ASD and the underlying neuroinflammatory pathways believed to contribute to the disorder.
Trial Design and Strategic Importance
The trial plans to enrol 150 paediatric patients under an adaptive design, allowing for pre-specified modifications based on interim data without compromising scientific integrity. This flexibility could prove critical in efficiently navigating the complexities of ASD treatment development. Neurotech is collaborating with international clinical and regulatory experts to ensure the study aligns with global standards and regulatory expectations.
Following the recent Human Research Ethics Committee approval announced in February, the activation of the Monash site marks a pivotal milestone. Additional clinical sites are expected to come online in the near future, broadening the trial’s reach and accelerating patient recruitment.
NTI164’s Potential and Market Context
NTI164 is a GMP-grade, multi-constituent cannabinoid formulation rich in CBDA and minor cannabinoids. Previous Phase I/II and II/III trials have demonstrated statistically significant and clinically meaningful benefits in ASD and related paediatric neuropsychiatric disorders, with a strong safety profile. The Beyond Harmony trial represents Neurotech’s most advanced effort to secure regulatory approval and ultimately commercialise a novel treatment option for a condition with significant unmet medical needs.
CEO Anthony For Filippis emphasised the importance of this development, highlighting the rigorous design of the trial and the company’s commitment to delivering meaningful outcomes for families affected by ASD.
Bottom Line?
As Neurotech expands its Phase 3 trial network, the coming months will be critical in determining NTI164’s path toward regulatory approval and market entry.
Questions in the middle?
- How quickly will additional clinical sites be activated and patients recruited?
- What interim data might emerge from the adaptive trial design, and how could it influence the study?
- What regulatory hurdles remain before NTI164 can achieve approval and commercialisation?